Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Cardiovascular agents

New heart failure drug extends survival by up to two years

A re-analysis of trial data reveals that the highly effective new drug sacubitril-valsartan could extend life by two years compared with enalapril for cardiovascular patients.

The heart failure drug sacubitril-valsartan reduces rates of cardiovascular death. Recent study shows that the treatment is also associated with a 1-2 year increase in life expectancy. In the image, MRI scan of patient who suffered heart failure

Source: Zephyr / Science Photo Library

Heart failure drug sacubatril-valsartan can reduce cardiovascular deaths and may also extend life compared with enalapril

The heart failure drug sacubitril-valsartan significantly reduces rates of cardiovascular death and hospitalisation compared with enalapril, the current standard of care, in patients with reduced ejection fraction.

A new analysis, published in The New England Journal of Medicine (online, 3 December 2015)[1], estimates that treatment with the drug is also associated with a one to two year increase in life expectancy compared with enalapril.

Researchers from the Brigham and Women’s Hospital in Boston, Massachusetts, re-analysed data on 8,399 patients from the PARADIGM-HF trial. They found a consistent effect on survival across patients aged 45–75 years. For example, a 65-year-old patient could expect to survive 11.4 years on sacubitril-valsartan compared with 10.0 years on enalapril.

The drug has been available since August 2015 on the Medicine and Healthcare products Regulatory Agency’s early access to medicine scheme, and received its EU marketing authorisation in November 2015.

Citation: Clinical Pharmacist DOI: 10.1211/PJ.2015.20200226

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • The heart failure drug sacubitril-valsartan reduces rates of cardiovascular death. Recent study shows that the treatment is also associated with a 1-2 year increase in life expectancy. In the image, MRI scan of patient who suffered heart failure

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.